This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:protocol:olmesartan:kidney_disease [08.13.2019] – [Animal studies] sallieq | home:protocol:olmesartan:kidney_disease [08.13.2019] – [Elevated kidney values tend to be temporary] sallieq | ||
---|---|---|---|
Line 7: | Line 7: | ||
- | ===== Subclinical kidney infection ===== | ||
- | Subclinical - that is to say, undetected or undetectable - kidney disease is common in patients with [[home: | ||
- | |||
- | Once patients activate the [[home: | ||
Line 47: | Line 43: | ||
" | " | ||
+ | |||
+ | ===== Subclinical kidney infection ===== | ||
+ | |||
+ | Subclinical - that is to say, undetected or undetectable - kidney disease is common in patients with [[home: | ||
+ | |||
+ | Once patients activate the [[home: | ||
===== Benefits of olmesartan for patients with kidney disease ===== | ===== Benefits of olmesartan for patients with kidney disease ===== | ||